The Adpn/Lep ratio, and the proposed cut-off points, may be an interesting and useful estimator of obesity- and MS-associated cardiometabolic risk, allowing the identification of a higher number of subjects at risk. This evidence concerns the gene ADIPOQ and myeloid sarcoma.